Fortress Biotech Announces First Patient Dosed in Phase II Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

Fortress Biotech, Inc. announced that the first patient was dosed in a multicenter, placebo-controlled and randomized Phase II clinical trial to evaluate Triplex, a cytomegalovirus (CMV) vaccine, when administered to human leukocyte antigen matched related stem cell donors to reduce CMV events in patients undergoing HSCT.